Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pilot captures jaw-dropping northern lights show from 36,000 feet (photos) - 2April full moon 2026 dazzles as 'Pink Moon' lights up skies worldwide (photos)
- 3What's the Fate of 5G Innovation?
- 4Vote In favor of Your Number one Cell phones
- 5Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport
- High velocity Internet services for Metropolitan Regions
- Nepal’s youngest premier sworn in after releasing new rap song about unity
- 13 must-see moon events in 2026: Eclipses, supermoons, conjunctions and more
- 1,000-mile Saharan dust storm, from the sky and from the ground
- IDF kills four terrorists equipped with weapons, surveillance gear near Gaza's Yellow Line
- Major Scottish gangland figure Steven Lyons arrested in Bali
- Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- Palestinians tell BBC they were sexually abused in Israeli prisons
- Don’t let food poisoning crash your Thanksgiving dinner
